Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Silver

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Internal Medicine|November 23, 2006
An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysisA K Agarwal, M R Silver, J E Reed, et al.
British Journal of Clinical Pharmacology|June 1, 1985
Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokineticsP D Kroboth, R B Smith, M R Silver, et al.
Clinical Pharmacology and Therapeutics|April 1, 1985
Effects of end-stage renal disease and aluminum hydroxide on temazepam kineticsP D Kroboth, R B Smith, R Rault, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 8, 1998
Barriers to adequate delivery of hemodialysisA R Sehgal, R J Snow, M E Singer, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Internal Medicine|November 23, 2006
An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysisA K Agarwal, M R Silver, J E Reed, et al.
British Journal of Clinical Pharmacology|June 1, 1985
Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokineticsP D Kroboth, R B Smith, M R Silver, et al.
Clinical Pharmacology and Therapeutics|April 1, 1985
Effects of end-stage renal disease and aluminum hydroxide on temazepam kineticsP D Kroboth, R B Smith, R Rault, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 8, 1998
Barriers to adequate delivery of hemodialysisA R Sehgal, R J Snow, M E Singer, et al.
Pageof 4